Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

prudentia.me

About Prudentia

Want to learn Go to prudentia.me and find the right courses for you. Get expert advice, hear what past students have to say, and build your own learning roadmap. We can also help you stay motivated and keep track of your progress.

Prudentia Headquarters Location

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Prudentia News

Mariner Endosurgery Announces Product Update to Flagship Surgical Visualization Technology LaparoGuard, an Augmented Navigation Platform

Feb 4, 2020

New features include the now-available Prudentia data analytics and post-operative review platform of LaparoGuard enabled procedures, and the announced development of Phylax intelligent cautery and energy device control module for LaparoGuard | Source: Mariner Endosurgery Hamilton, ON, Feb. 04, 2020 (GLOBE NEWSWIRE) -- Mariner Endosurgery Inc., an innovative Canadian medical device company leading the commercialization of computer-assisted medical devices for laparoscopic surgeries, announced today the U.S. and Canadian availability of updates to its flagship surgical visualization technology, LaparoGuard. LaparoGuard is a novel augmented surgical navigation system that enables surgeons to annotate areas of 3D safety zones during minimally invasive procedures. The latest product updates strengthen the visualization platform by adding Prudentia, a data analytics tool that allows for post-operative review of surgical instrument movements, and safe zone reconstructions. Prudentia permits user front-end customization to visually represent the surgical case to enhance risk mitigation and surgical education. Mariner's flagship product LaparoGuard is a novel soft-tissue surgical navigation platform designed to amplify the safety profile and assist surgeons in delivering a superior quality of care to their patients. "We have listened carefully to our customers and surgeons and are pleased to announce the expansion of our post-operative data analytics module Prudentia," commented Mitch Wilson, President & COO of Mariner Endosurgery. "We are also pleased to announce the accelerated development of Phylax, an enhancement of LaparoGuard that empowers the surgeon to add intelligence to cautery and other energy devices by syncing our core LaparoGuard safe zone technology to controlling energy delivery." Mariner Endosurgery plans to pursue major market regulatory approval of Phylax, and adoption by leading healthcare facilities, and upon approval will market Phylax as part of the LaparoGuard platform. About Mariner Endosurgery Mariner Endosurgery Inc. is a Hamilton-based company that develops and commercializes innovative computer-assisted medical devices for future-facing laparoscopic surgeries. Their flagship product LaparoGuard is a novel soft-tissue surgical navigation platform that augments visualization and is designed to enhance the safety profile to assist surgeons in delivering a superior quality of care to their patients. Mitch Wilson, President & COO905-921-8755mwilson@marinerendosurgery.comDavid A. Langlois, MD, Chief Medical Officerdlanglois@marinerendosurgery.comMariner Endosurgery Inc.175 Longwood Road SouthMcMaster Innovation ParkHamilton, ONL8P 0A1Canada Related Articles

    Discover the right solution for your team

    The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

    Request a demo

    CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.